InvestorsHub Logo
Followers 8
Posts 1295
Boards Moderated 0
Alias Born 04/13/2016

Re: Omayr post# 7506

Friday, 11/18/2016 11:01:39 AM

Friday, November 18, 2016 11:01:39 AM

Post# of 233118
My theory is that CYDY has enough cash to fund the p3 adjunct which should have results/fda approval 1st q 2017. so, not likely there will be another cash raise until after that. i also don't think the SP will rise significantly until we are closer to full patient trial enrollment and then trial results. patient enrollment could be announced any day this year. at the current price i think its a buy.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News